Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Clinical and Experimental Immunology|August 1, 2020
Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitisS C Sasson, J J Zaunders, K Nahar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2016
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabA M Menzies, D B Johnson, S Ramanujam, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2019
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanomaY J L Jansen, E A Rozeman, R Mason, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 3, 2020
Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanomaM T Tetzlaff, C Adhikari, S Lo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 11, 2020
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆C N Owen, A N Shoushtari, D Chauhan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2023
Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trialsJ M Versluis, A M Menzies, K Sikorska, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2018
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanomaM T Tetzlaff, J L Messina, J E Stein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 6, 2023
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemiaS H Cass, J W D Tobin, Y D Seo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 2, 2021
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanomaC N Owen, X Bai, T Quah, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2025
Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanomaR V Rawson, N G Maher, A M Menzies, et al.
Pageof 4